Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance

J Infect Dis. 2017 Dec 1;216(suppl_9):S824-S828. doi: 10.1093/infdis/jix413.

Abstract

Healthcare delivery has advanced due to the implementation of point-of-care testing, which is often performed within minutes to hours in minimally equipped laboratories or at home. Technologic advances are leading to point-of-care kits that incorporate nucleic acid-based assays, including polymerase chain reaction, isothermal amplification, ligation, and hybridization reactions. As a limited number of single-nucleotide polymorphisms are associated with clinically significant human immunodeficiency virus (HIV) drug resistance, assays to detect these mutations have been developed. Early versions of these assays have been used in research. This review summarizes the principles underlying each assay and discusses strategic needs for their incorporation into the management of HIV infection.

Keywords: HIV; drug resistance; point-of-care tests.

Publication types

  • Review
  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-HIV Agents / therapeutic use*
  • Drug Resistance, Viral
  • HIV / drug effects*
  • HIV / genetics
  • HIV Infections / drug therapy*
  • HIV Infections / virology
  • Humans
  • Point-of-Care Testing*
  • Reverse Transcriptase Polymerase Chain Reaction

Substances

  • Anti-HIV Agents